Springer Nature SharedIt Content-Sharing Initiative

Since 2016, Springer Nature has been helping its authors bring more attention to their work by creating shareable links to view-only versions of their peer-reviewed research papers that can be freely-distributed to their potential readers via an initiative called SharedIt.

What is SharedIt?

“SharedIt is a content sharing initiative from Springer Nature that allows authors and subscribers to easily and legally share links to free-to-read versions of research articles anywhere, including social media platforms, repositories and personal websites. All articles published in the Springer Nature owned journal portfolio and over 1,000 co-owned or partner-owned journals are included in the initiative.”

What many authors and readers do not realize is that the mass sharing of downloaded PDFs of peer-reviewed, published journal articles is usually not allowed within standard copyright agreements. The SharedIt initiative makes the sharing legal because the article PDF can only be downloaded and printed if the article has been published as an open access paper or if the viewer has a personal or institutional subscription through which they may gain access to the full-text PDF. For everyone else, the article in its entirety can be read in a free, view-only version but cannot be downloaded/saved/printed. The information, however, can still be read and further shared via the paper’s SharedIt link, even via far-reaching social media channels.

To learn more about SharedIt – see:

…or AskUs at the MSK Library.

Promise for Targeted Lung Cancer Treatments

A recent Today Show segment features MSK’s Dr. Helena Yu, discussing successes of targeted lung cancer treatments.

Dr. Helena Yu, right, appearing on the Today Show.

Dr. Helena Yu, right, appearing on the Today Show.

These therapies are discussed in greater depth in a Medpage Today article that quotes MSK’s Dr. Alexander Drilon and an Oncology Nursing News interview with MSK’s Michael D. Offin. Immunotherapy and other new treatments are increasing survival in many patients, often by targeting specific, less-common genetic mutations like BRAF, RET, MET, and NTRK.

A Cancer Network article describes early research by MSK’s Dr. Alison Schram on solid tumors, including lung tumors, with NRG1 gene fusion. Therapy targeting this rare gene fusion in a patient with non-small cell lung cancer reduced the tumor size in the lung and in brain metastases.